Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 30 Publications

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTEPWJsPcLizszN MkfoOFjDqGh? NFr1NZNjdG:la4OgNlcuV0iFLXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHPvcZBiemGkbHWgeI8hfGijdDDv[kBj[XOjbDDs[ZZmdHN? NFLvfW4zPjN3MEW2OS=>
NP69 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PDTmlEPTB;M{GuOlnDuTJwNUSg{txO MUOyOlI2OjV5NR?=
NP460 NE[3[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJ{Lki1xtEyNjF6IN88US=> MUSyOlI2OjV5NR?=
C666-1 NVjhS4x3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF7Lkm1xtE5Njl|IN88US=> MUSyOlI2OjV5NR?=
C666-1 M{HWSWNmdGxiVnnhZoltcXS7IFHzd4F6 NWHNN|AzOTBiwsXN M4rUcFQ5KGh? M4LC[2ROW09? NUXPUppMe2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gZ4l{eGyjdHnu MkPxNlYzPTJ3N{W=
C666-1  MmTZSpVv[3Srb36gRZN{[Xl? M{PQXlExKML3TR?= M2TyWlI1KGh? MoexSG1UVw>? MYfhZ5RqfmG2ZYOgeIhmKHB3MzDwZZRpf2G7LDD1dJJm\3WuYYTpcocheDV|LDDwNlEh[W6mIF3kcVI> NGfKd24zPjJ3MkW3OS=>
C666-1 NYXOU4RISXCxcITvd4l{KEG|c3H5 MkTCNVAhyrWP Mn[5OFgwPzJiaB?= NWPrT41ZTE2VTx?= NV[2[I5De2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8h[2m|cHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ NHTPdmYzPjJ3MkW3OS=>
A549 NUnPSWVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKyOEBp NF;TVIdKSzVyPUG3MlY5KMLzIESuOVIh|ryP NGrmPZkzPjF{NUKzNC=>
A549-NTC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XpSlI1KGh? NF;EOlBKSzVyPUG5MlQzKMLzIEGuPVYh|ryP NEfPN2MzPjF{NUKzNC=>
A549-920 NEPyU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzVNlQhcA>? MWPJR|UxRTN|Lki1JOKyKDRwOESg{txO Mkm1NlYyOjV{M{C=
CRL-5908 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnr[ottOjRiaB?= NFjlWFRKSzVyPUO4MlcyKMLzIEKuOFMh|ryP NUHkdotXOjZzMkWyN|A>
L6 M1PsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC2NVDDqM7:TdMg MkDyNlQwPDhxN{KgbC=> Mn;RSG1UVw>? Mkm2bY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v NXn1W5FSOjV6N{G3PVQ>
C2C12 NUTCbncyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj6N|RPOTEEoN88UeKh M2rBW|I1NzR6L{eyJIg> NYXmeIp5TE2VTx?= NWXte3U1cW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w NWDDPVBmOjV6N{G3PVQ>
MCF-7  NH\QT|RHfW6ldHnvckBCe3OjeR?= Mnj5NVDDqM7:TR?= Mn7wSG1UVw>? M3PRVolvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>? NEn4fYMzPTdyMkewNy=>
DU4475  NIjoTVNHfW6ldHnvckBCe3OjeR?= MnuyOU8yOC9{MDFOwG0> NW\lbmVSOjUEoHi= MnXa[I94dnKnZ4XsZZRmeyCWb3PhMVEh\G:|ZTDk[ZBmdmSnboTsfS=> MXKyOVU1PzF5NB?=
SMMC-7721 MkC0SpVv[3Srb36gRZN{[Xl? NELTTXgyOCEQvF2= M3PJOlQ5KGh? Moq3SG1UVw>? MnHhZ4F2e2W|IFTORUBFW0JiZHHtZYdm NWDJ[IlnOjV3NESzOlE>
SMMC-7721 MVPGeY5kfGmxbjDBd5NigQ>? MmDENVAh|ryP MX20PEBp MWXEUXNQ NVvLZ5hncW6mdXPld{B1cGViY3jyc41ifGmwLXLveY5lKHC{b4TlbY4hUU[LMU[geI8heGG{dHnhcIx6KGyxY3HsbZpmKGmwIITo[UBkgXSxcHzhd43DqA>? NGTMd|IzPTV2NEO2NS=>
SMMC-7721 MofPSpVv[3Srb36gRZN{[Xl? NULjcnJ7OTBizszN NYexc4R3PDhiaB?= NV3iXXp2TE2VTx?= NWewNGRKcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mxsBKTk6EMdMgcXJPSQ>? Mn7PNlU2PDR|NkG=
SMMC-7721 NEDlbIZHfW6ldHnvckBCe3OjeR?= M4PvSFExKM7:TR?= NGGwcI4{PiCq M4LpcGROW09? NF7YT29k[XW|ZYOgeIhmKGWldH;wbYMh\XiycnXzd4lwdiCxZjDJSmkyPg>? MYWyOVU1PDN4MR?=
MCF-7 NUm2O5Z{TnWwY4Tpc44hSXO|YYm= MW[xNOKh|ryP MVqwMVI1KGh? M4Dp[4lv\HWlZYOgdFU{KGGwZDDwNlEwS2myMR?= M3zYfVI2PDh{M{ez
OVCAR10 M2m2SmZ2dmO2aX;uJGF{e2G7 NGjlc3IyOMLizszN M13uRlIycMLi MmL5SG1UVw>? NGnkfXNqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ MUSyOVQzPjV2OB?=
NCI-H23 MUTGeY5kfGmxbjDBd5NigQ>? MlfSNVDDqM7:TR?= M1rPclIycMLi NVvNT4J3TE2VTx?= NUX3XGZycW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? NYPJflFpOjV2Mk[1OFg>
A2780 Ml;NSpVv[3Srb36gRZN{[Xl? MnnRNVDDqM7:TR?= Ml2yNlFpyqB? M3jVTmROW09? NXPSdopvcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? M4HUVFI2PDJ4NUS4
NCI-H23 MV\GeY5kfGmxbjDBd5NigQ>? M2S3WFExyqEQvF2= MXOyNYjDqA>? MX7EUXNQ NHrt[YVl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> M3nMdlI2PDJ4NUS4
A2780 M4\mcGZ2dmO2aX;uJGF{e2G7 NGLlW4gyOMLizszN NVr3O5dSOjGqwrC= NWr0Rm5bTE2VTx?= MXLk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= NF\JR|czPTR{NkW0PC=>
HCT116  NFv0OVVHfW6ldHnvckBCe3OjeR?= MlOyNVAhyrWP MV[yOEBp MlHPZ4F2e2W|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6 MoTRNlU{QDByNUW=
MCF-10CA1a MVPGeY5kfGmxbjDBd5NigQ>? MonlNVDDqM7:TR?= Ml61OFghcA>? NXezNG5STE2VTx?= MlnTbY5pcWKrdIOgZoF{[WxiaX72ZZNqd25iYX7kJJJm\HWlZXSgWGdHNc7{Mz3pcoR2[2WmIHnueoF{cW:wIITvJIJie2GuIHzleoVtew>? NHXCRpozPTJ3N{eyPS=>
MCF-10A1  M1j3[2Z2dmO2aX;uJGF{e2G7 NFHz[nIyOMLizszN M{CzVlI1NzR6IHi= MYfEUXNQ Mk\ibY5pcWKrdIOgcYloemG2aX;uJI9nKG6xcn3hcEBjemWjc4Sg[ZBqfGinbHnhcOKh NGLqNmMzPTJ3N{eyPS=>
MCF-10CA1a NVnrfGo{TnWwY4Tpc44hSXO|YYm= M4jwPVExyqEQvF2= MV2yOEBp MYLEUXNQ Mnz3[IVkemWjc3XzJJRp\SCWR1[t{tI{NWmwZIXj[YQhdVKQQTDs[ZZmdHNib3\NUXAzNMLiTV3QPUwh[W6mwrDpcpRm\3KrbtMg{tLDqDN? NHfidpgzPTJ3N{eyPS=>
MCF-10CA1a M3nSeWZ2dmO2aX;uJGF{e2G7 NXPFSnllOTEEoN88US=> NEj5UXgzPCCq NXjGNlQyTE2VTx?= MmDvbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MW[yOVI2Pzd{OR?=
SK-BR-7 M4foR2Z2dmO2aX;uJGF{e2G7 MkHONVDDqM7:TR?= NWqxUmcxOjRiaB?= NXvkVJFITE2VTx?= NHTOcXhqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NUfkcmlXOjV{NUe3Nlk>
SUM102PT NGGxbm1HfW6ldHnvckBCe3OjeR?= M3;0clExyqEQvF2= NXfOR4E6OjRiaB?= MmfaSG1UVw>? MY\pcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? MYOyOVI2Pzd{OR?=
RAW 264.7 NFq0OY9HfW6ldHnvckBCe3OjeR?= MXKxNOKh|ryP NFjHWFQ{OCCvaX6= MmfidJJmfmWwdIOgeIhmKHB3MzDy[YR2[3Srb36gbY4hemW|cH;ud4UhfG9iTGDT NIG2SIkzPTF5MkW0Oy=>
RAW 264.7 NXvkVnV3TnWwY4Tpc44hSXO|YYm= MWmxNOKh|ryP NFywNmw{OCCvaX6= NF\1UXZz\WS3Y3XzJJRp\SCOUGOtZZVodWWwdHXkJJRp\SCQRj5OvmIhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIFkfGm4aYT5 MViyOVE4OjV2Nx?=
RAW 264.7 NXfUR3lMTnWwY4Tpc44hSXO|YYm= MnTBNVDDqM7:TR?= M1fNeFMxKG2rbh?= M2TLSYlvcGmkaYTzJGxRWy2rbnT1Z4VlKE6RIIDyc4R2[3Srb39CpC=> NV:1T|A4OjVzN{K1OFc>
MCF7  MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVzURolFOi53INM1US=> MmPTOUBl MkLKSG1UVw>? NVzXOlFMe2Wwc3n0bZpmeyCPQ1[3JJRwKFCDUmCgbY5pcWKrdHnvci=> Mof4NlUxQDV7MEK=
MCF7  M4HmVWZ2dmO2aX;uJGF{e2G7 M1m1dVIvPSEEtV2= MXK0PEBp MX\EUXNQ MXvk[YNz\WG|ZYOgeIhmKGixbX;sc4dwfXNiRGPCJJJmeGGrcjDmdoVyfWWwY3nldy=> NV2yVlVUOjVyOEW5NFI>
ACHN NUP5[YpNS2WubDDWbYFjcWyrdImgRZN{[Xl? NWXEfWc{OC53LUGwJO69VQ>? M{SydlAuPiCm NHj1SINFVVOR MmPqbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NI\jWlQzPTB4N{e4Oy=>
Caki-2 Ml;nR4VtdCCYaXHibYxqfHliQYPzZZk> MYGwMlUuOTBizszN MlnRNE03KGR? Moj3SG1UVw>? NFzVUZZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnvlNlUxPjd5OEe=
A498 NWj3PHNOS2WubDDWbYFjcWyrdImgRZN{[Xl? MUKwMlUuOTBizszN MVOwMVYh\A>? NH;GeYJFVVOR M2DpVIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MX2yOVA3Pzd6Nx?=
115 M3nB[mNmdGxiVnnhZoltcXS7IFHzd4F6 Mli2NE42NTFyIN88US=> NF;zR2ExNTZiZB?= MojRSG1UVw>? Mmm0bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXeyOVA3Pzd6Nx?=
117 NFfwRVRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFTreYsxNjVvMUCg{txO MmXYNE03KGR? NVX5THN7TE2VTx?= MlvQbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3L1cFI2ODZ5N{i3
ACHN NFjPXJVHfW6ldHnvckBCe3OjeR?= NFnDV|UxNjVxMT:1JO69VQ>? NFrqe3I1QCCq NUix[o9OTE2VTx?= MlTNcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NYXKUFR6OjVyNke3PFc>
Caki-2 MoLMSpVv[3Srb36gRZN{[Xl? MkTqNE42NzFxNTFOwG0> M1PHflQ5KGh? NHT0WIVFVVOR NHrWZnNt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NITHcI4zPTB4N{e4Oy=>
A498 NFnmfm1HfW6ldHnvckBCe3OjeR?= NYDic4FVOC53L{GvOUDPxE1? MmDUOFghcA>? MVLEUXNQ M{fuXIxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz MXGyOVA3Pzd6Nx?=
115 MlKzSpVv[3Srb36gRZN{[Xl? M{ewe|AvPS9zL{Wg{txO NVr5[lRJPDhiaB?= NH7tbWZFVVOR MXHs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MknoNlUxPjd5OEe=
ACHN MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\UUGU2KM7:TR?= MlzjOFghcA>? NIXMTnhFVVOR NUn2dXJmcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh NH;iWW0zPTB4N{e4Oy=>
Caki-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv0OUDPxE1? M3\sSFQ5KGh? NFnqc3BFVVOR NGTHSGFqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> NW\3TWRMOjVyNke3PFc>
A498 NXfHS3lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmqzOUDPxE1? NEK4fXM1QCCq MoHCSG1UVw>? NFyzWXVqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> MlHaNlUxPjd5OEe=
115 MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrnUHAzPSEQvF2= NUnMVFVmPDhiaB?= NX\aOoY1TE2VTx?= M2fNO4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MXOyOVA3Pzd6Nx?=
ACHN NWHRc4s{TnWwY4Tpc44hSXO|YYm= NV\wVmRFPSEQvF2= MkP5OFghcA>? Ml20SG1UVw>? MofDbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= MkTaNlUxPjd5OEe=
Caki-2 NYXa[ZVtTnWwY4Tpc44hSXO|YYm= MlnKOUDPxE1? M3:0V|Q5KGh? NVi1Voh{TE2VTx?= M1r1b4lv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= MYiyOVA3Pzd6Nx?=
A498 Ml34SpVv[3Srb36gRZN{[Xl? M2Hq[|Uh|ryP MoHYOFghcA>? MV3EUXNQ M{LVWolv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= M2nPflI2ODZ5N{i3
115 M1fN[mZ2dmO2aX;uJGF{e2G7 NH31bpo2KM7:TR?= NXXOTWN5PDhiaB?= MoD6SG1UVw>? MWfpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MlnFNlUxPjd5OEe=
MOLM-13 M{\EUmZ2dmO2aX;uJGF{e2G7 MnexOuKh|ryP Mk\wNE05KGh? NV\xRmdbTE2VTx?= MnfNbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicEWzMEBOTE1{LDDwNlEh[W6mIHHj[ZR6dGG2ZXSgdFU{ NF\wfZgzPDh6NUC4Ni=>
MOLM-13 MV\GeY5kfGmxbjDBd5NigQ>? NVrjfGJHPsLizszN Mn\uOkBp NYDIdYpsTE2VTx?= NFPlcWxmdmijbnPld{B1cGViYXPleJlt[XSrb36gc4YhcGm|dH;u[UBJOkJiYX7kJIhm[XRic3jvZ4sheHKxdHXpcpMhUHOyMkegZY5lKEi|cEmw MlW4NlQ5QDVyOEK=
HepG2 NWLMdFlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG3NkBp MV3EUXNQ NGD6V|JKSzVyPUO1Mlg3KMLzIEKuPUDPxE1? MYOyOFg5PDhyOR?=
HepG2/As Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXG3NkBp M4XuRmROW09? MnrXTWM2OD14OD6xN{DDuSB7Lk[g{txO MYWyOFg5PDhyOR?=
SMMC7721 M{fNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jNeVczKGh? NXLvbJIyTE2VTx?= M17oV2lEPTB;M{GuNlghyrFiND6yJO69VQ>? MoPvNlQ5QDR6MEm=
SMMC7721/Ac NXTFXVhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnObYtTPzJiaB?= MoO4SG1UVw>? NWjuPYlpUUN3ME21OU4zOSEEsTC1MlA{KM7:TR?= NFPWdGIzPDh6NEiwPS=>
Huh-7 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjKellNPzJiaB?= NG\1flFFVVOR M2m3T2lEPTB;M{OuPVYhyrFiMz65JO69VQ>? NHi5UIEzPDh6NEiwPS=>
Hep3B Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PLfVczKGh? MoL4SG1UVw>? MoHoTWM2OD1{MD6xPEDDuSBzLki0JO69VQ>? NVjOVYhZOjR6OES4NFk>
HepG2 NEfh[2lCeG:ydH;zbZMhSXO|YYm= NEOyUXZqdmS3Y3XzJIFxd3C2b4Ppdy=> NV:0VJRMOjR6OES4NFk>
SMMC7721 NHTPPGlCeG:ydH;zbZMhSXO|YYm= M{\yRolv\HWlZYOgZZBweHSxc3nz NGrmXG8zPDh6NEiwPS=>
Huh-7 M{fsbmFxd3C2b4Ppd{BCe3OjeR?= MVnpcoR2[2W|IHHwc5B1d3Orcx?= NG\GfVkzPDh6NEiwPS=>
Hep3B NGD3TJdCeG:ydH;zbZMhSXO|YYm= M2nocolv\HWlZYOgZZBweHSxc3nz NF71bHEzPDh6NEiwPS=>
U2OS  MXXGeY5kfGmxbjDBd5NigQ>? MWSyNEDPxE1? M1XZb|I1KGh? NILk[FBqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCEQ1yyRVEtKEKFTGjMxsBidmSEQ1zX NYXqdW5TOjR6NkeyOVk>
AML2 MnnDRZBweHSxc3nzJGF{e2G7 NYPr[YxFOi9zMDFOwG0> M1Pm[|I1NzR6IHi= NVTCW4dVcW6mdXPld{BieG:ydH;zbZM> M1\UXlI1PjV7N{S5
MOML13 NWnSdGhYSXCxcITvd4l{KEG|c3H5 MWSyM|ExKM7:TR?= NHzjd4wzPC92ODDo MUXpcoR2[2W|IHHwc5B1d3Orcx?= MX[yOFY2QTd2OR?=
AML2 M3jm[GZ2dmO2aX;uJGF{e2G7 NFnlS40yOM7:TR?= MnHSNk81KGh? M{PFbYlv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz NGqwUWQzPDZ3OUe0PS=>
AML3 NIO2WmVHfW6ldHnvckBCe3OjeR?= NH7kcVcyOM7:TR?= NEflVFczNzRiaB?= Ml7zbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= MoHvNlQ3PTl5NEm=
MOML13 M2SxbmZ2dmO2aX;uJGF{e2G7 MoLUNVDPxE1? NVu4T|I2Oi92IHi= NYPvXlBScW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> NIjWdYczPDZ3OUe0PS=>
BeWo NVHST2RMTnWwY4Tpc44hSXO|YYm= NIq5OnQ{OCEEtV2= NF3iUW4zPCCq M1H5W4lv[3KnYYPld{BxPTNuIF3kcVItKHB{MTDhcoQhWHWvYTDheEB1cGVicILveIVqdiCuZY\lcC=> MUiyOFQ6QDF3NB?=
BeWo MmDrRZBweHSxc3nzJGF{e2G7 MVyzNEDDvU1? MXOyOEBp M1;CdYlv[3KnYYPld{BieG:ydH;zbZM> M2TkRVI1PDl6MUW0
OCI MmrYSpVv[3Srb36gRZN{[Xl? NG[1[4syOCEQvF2= M2TaclI1KGh? NHT6SYZ2eHKnZ4XsZZRmeyC2aHWgV29EWy1zIHX4dJJme3Orb36= Mlr5NlQ1PzN3NkK=
MOLM MUnGeY5kfGmxbjDBd5NigQ>? NWq4bGJ2OTBizszN M{niXFI1KGh? M1rlSZVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= MV[yOFQ4OzV4Mh?=
U2OS  M33K[mZ2dmO2aX;uJGF{e2G7 NGDYN2czOCEQvF2= M2XPWFI1KGh? Mo\vbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>? MlznNlQ{PjZyMEe=
RKO Ml\RSpVv[3Srb36gRZN{[Xl? NGm1W5EzOCEQvF2= MXeyOEBp NIrU[JJqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw MXuyOFM3PjByNx?=
U2OS  NFnxOoVHfW6ldHnvckBCe3OjeR?= MYmyNEDPxE1? NIrEd4IzPCCq MkXxbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= M3\XUlI1OzZ4MEC3
RKO NFvs[FdHfW6ldHnvckBCe3OjeR?= NU[xWXRHOjBizszN NVj2cYwxOjRiaB?= NIjUWVhqdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> NFLiTVIzPDN4NkCwOy=>
SMMC-7721  MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mn7HNU4zPS1{MDFOwG0> NGrwNXgzPC92OD:3NkBp M2LzPWROW09? M4TRPYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 Mkn0NlQzQDZ|MUK=
HuH-7 NX\Zd|JrS2WubDDWbYFjcWyrdImgRZN{[Xl? MVqxMlI2NTJyIN88US=> NYjrPFFWOjRxNEivO|IhcA>? NH3RS|FFVVOR M4LROYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 NXG0Z3BYOjR{OE[zNVI>
SMMC-7721  NX\CRXBzSXCxcITvd4l{KEG|c3H5 MXOyNEDPxE1? M3LPbFQ5KGh? M3e4ZWROW09? MUnpcoR2[2W|IHHwc5B1d3Orcx?= NI\KVGMzPDJ6NkOxNi=>
HuH-7 M1nhfWFxd3C2b4Ppd{BCe3OjeR?= M3XSXFIxKM7:TR?= M4j0XlQ5KGh? M13n[WROW09? M4LzVIlv\HWlZYOgZZBweHSxc3nz MYiyOFI5PjNzMh?=
SMMC-7721  NH7pcG1HfW6ldHnvckBCe3OjeR?= NVLoO4lvOTBizszN MVSzOkBp M13qemROW09? MkLQ[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> NFSzXo0zPDJ6NkOxNi=>
HuH-7 NF3Qd3ZHfW6ldHnvckBCe3OjeR?= NX7EemVJOTBizszN M{H5V|M3KGh? M{THOGROW09? NF:2fnpld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? M4SxSlI1Ojh4M{Gy
AT2 NGLMW|RHfW6ldHnvckBCe3OjeR?= NWrjcphIPS9zMDFOwG0> NXLuXG51dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= MoHJNlQzPDB{MEO=
REH MojlSpVv[3Srb36gRZN{[Xl? NUn6N2N3PS9zMDFOwG0> MXjs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? MlXQNlQzPDB{MEO=
UoCB6 NWrmfok3TnWwY4Tpc44hSXO|YYm= NFrn[mY2NzFyIN88US=> Ml70cIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? MoPQNlQzPDB{MEO=
AT2 NYS4UXg3S2WubDDWbYFjcWyrdImgRZN{[Xl? MX2wMVI2KM7:TR?= NH7yRllqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MoDQNlQzPDB{MEO=
REH NGWw[WJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXzZU4R4OC1{NTFOwG0> MXPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MnqxNlQzPDB{MEO=
UoCB6 NHv5SWtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1O4TVAuOjVizszN MoTLbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MWWyOFI1ODJyMx?=
A2780 NXz6eo9DTnWwY4Tpc44hSXO|YYm= NFjTb|k2NzFyL{KwJO69VQ>? MWKyOEBp MlvOeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NHLocHMzPDF|NkG0Oy=>
H460 MmX6SpVv[3Srb36gRZN{[Xl? M2PoWFUwOTBxMkCg{txO NHXMbJczPCCq NFH4RWV2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= NGHNSoozPDF|NkG0Oy=>
Lovo  MkjvSpVv[3Srb36gRZN{[Xl? NGXjVoI2NzFyL{KwJO69VQ>? NF2wSFkzPCCq MmDweZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? M{HI[|I1OTN4MUS3
A2780 MW\BdI9xfG:|aYOgRZN{[Xl? MU[1M|ExNzJyIN88US=> MX:yOEBp NXW3flI2\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? M2LhclI1OTN4MUS3
H460 M2LVR2Fxd3C2b4Ppd{BCe3OjeR?= M{T4[|UwOTBxMkCg{txO Ml;GNlQhcA>? NE\MfndmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? MX6yOFE{PjF2Nx?=
Lovo  M2nzZWFxd3C2b4Ppd{BCe3OjeR?= NEHud4U2NzFyL{KwJO69VQ>? NIfZVY4zPCCq MoX2[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> M3fUSlI1OTN4MUS3

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MDM2 / p53 / ALKBH2 / p21 / PUMA; 

PubMed: 23258843     


CCF-STTG1 cells were treated with the MDM2 antagonist nutlin-3 (0–8 µM) for 24h before cell lysates were collected for western blotting.

RRM1 / RRM2 / p53R2 / p21 / p53 / pS6 / S6; 

PubMed: 28507282     


(A) Rh18 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. (B) Rh30 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. GAPDH and Actin served as loading controls.

23258843 28507282
Immunofluorescence
Lamin A / Lamin C / p16 / H3K9me3; 

PubMed: 30728349     


c Immunofluorescence images of nuclear deformation and p16 expression after Nutlin-3 treatment for different time period. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were subjected to immunofluorescence staining for Lamin A/C (Red), p16 (Green), and counterstained with DAPI (Blue). dImmunofluorescence images of nuclear deformation and decreased expression of H3K9me3 in HCT p53+/− cells (left). Counting of histone H3K9me3-positive cells (middle) and signal intensities (right) on the basis of IF staining. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were IF stained with Lamin A/C (Red), H3K9me3 (Green), and counterstained with DAPI (Blue). *P < 0.05. 

Merlin / cyclin D1 / p53 / MDM2; 

PubMed: 30274821     


The changes in the subcellular localization of proteins in response to Nutlin-3. Nuclear merlin was indicated with white arrows. Scale bar = 50 μm.

p53; 

PubMed: 24286312     


The subcellular localization of p53 was detected under immunofluorescence microscope (1,000×). The cells were treated as indicated and stained for p53 (red). Nuclei were counterstained with DAPI (blue).

30728349 30274821 24286312
Growth inhibition assay
Cell viability; 

PubMed: 29286113     


Inhibitory effect of nutlin-3 for the cell proliferation after cultivate cells at different concentration for three times (24, 48 and 72 h), respectively.

29286113
In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

- Collapse

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

- Collapse
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID